Biotek-snakken — April 2026
-
Desuden forventes det så vidt jeg husker, at registreringsansøgningen i GEA indsendes i Q2, så jo før des bedre- håber lidt at disse nyheder under normale omstændigheder ville hive os i nærheden af kurs 30, men i Trump verdenen er det jo umuligt at vurdere. Verden styres af lunatics - forfærdeligt.
-
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced that Gilead Sciences, Inc. has exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera, under their
Yahoo Finance (finance.yahoo.com)
-
Gilead køber Tubulis hvis førende ADC sigter mod NaPi2b og har leveret data nogenlunde på niveau med Zymeworks ZW191 som er et ADC mod FRa - synes prisen på 3,1 milliarder dollars plus 1,85 milliarder dollars i milestones virker ret højt i forhold til Zymeworks markedsværdi på 2 milliarder dollars.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind